A randomized, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the pharmacodynamics, pharmacokinetics, safety and tolerability of orally inhaled indacaterol administered via the EPIC test fixture and the Concept1 device
Read time: 1 mins
Last updated:11th Apr 2013
To assess the bronchodilator effect of once-daily lactose-blended (LB) indacaterol administered via the EPIC test fixture and Concept1 in adult patients with persistent asthma compared with placebo as measured by trough FEV1 after 3 days of treatment.
|Study start date||2013-04-11|